UCB SA (OTCMKTS:UCBJF) Receives Average Rating of “Moderate Buy” from Analysts

UCB SA (OTCMKTS:UCBJF) has earned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and five have issued a buy rating on the company.

A number of equities analysts have weighed in on the stock. Jefferies Financial Group raised shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Piper Sandler reissued a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd.

UCB Stock Performance

Shares of OTCMKTS UCBJF opened at $236.94 on Monday. UCB has a 12-month low of $228.94 and a 12-month high of $345.39. The firm’s 50-day simple moving average is $252.82 and its 200 day simple moving average is $279.78. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on developing and commercializing medicines for severe diseases, particularly in immunology and neurology. The company’s research and development activities target conditions such as inflammatory disorders, epilepsy, and other diseases affecting the central nervous system.

UCB’s portfolio includes Bimzelx (bimekizumab) for certain inflammatory conditions, Cimzia (certolizumab pegol) for immune-mediated diseases, and Fintepla (fenfluramine), Briviact (brivaracetam), Keppra (levetiracetam), and Nayzilam (midazolam) for seizure-related disorders.